HSBC said risk-reward turned favourable post corrections in Cadila Healthcare & Cipla.
Moneycontrol News
@moneycontrolcom
Cadila Healthcare shares gained 0.6 percent and Cipla 0.8 percent in morning on Monday after global research house HSBC upgraded both stocks to buy.
The investment firm said risk-reward turned favourable post corrections in Cadila Healthcare & Cipla. Stocks lost 20 percent and 16 percent in last one year.
It also has a buy call on Aurobindo Pharma, Torrent Pharma, Divis Labs, Biocon & Ipca Labs.
2018 was another tough year for pharma companies but headwinds are expected to persist in 2019, HSBC said.
At 10:23 hours IST, Cadila Healthcare was quoting at Rs 345.90, up 0.36 percent and Cipla was up 0.28 percent at Rs 514.85 on the BSE.
Disclaimer: The above report is compiled from information available on public platforms. Moneycontrol advises users to check with certified experts before taking any investment decisions.First Published on Jan 7, 2019 10:28 am
